Pharvaris (NASDAQ:PHVS) Reaches New 52-Week Low – Here’s What Happened

Pharvaris (NASDAQ:PHVS) reached a new 52-week low during trading on Thursday . The stock traded as low as $14.00 and last traded at $14.85, with a volume of 294 shares changing hands. The stock had previously closed at $14.95.

Wall Street Analysts Forecast Growth

Separately, JMP Securities lifted their target price on shares of Pharvaris from $46.00 to $55.00 and gave the company a “market outperform” rating in a report on Friday, January 31st.

Pharvaris Trading Down 0.5 %

The company has a market capitalization of $778.08 million, a PE ratio of -5.31 and a beta of -3.02. The business’s 50-day simple moving average is $16.49 and its two-hundred day simple moving average is $18.80.

Institutional Investors Weigh In On Pharvaris

A number of hedge funds have recently bought and sold shares of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in shares of Pharvaris during the third quarter worth about $906,000. HighVista Strategies LLC grew its position in shares of Pharvaris by 35.9% in the 3rd quarter. HighVista Strategies LLC now owns 22,768 shares of the company’s stock worth $422,000 after acquiring an additional 6,018 shares in the last quarter. Patient Square Capital LP bought a new stake in shares of Pharvaris in the 3rd quarter valued at approximately $4,488,000. State Street Corp acquired a new stake in shares of Pharvaris during the 3rd quarter valued at approximately $1,000,000. Finally, Sphera Funds Management LTD. raised its position in shares of Pharvaris by 8.9% during the 3rd quarter. Sphera Funds Management LTD. now owns 439,292 shares of the company’s stock valued at $8,136,000 after acquiring an additional 36,027 shares in the last quarter.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.